Igc Pharma Inc (IGC)

$0.28 -0.01 (-2.63%)
Market Cap 27.07M
Revenue (ttm) 1.27M
Net Income (ttm) -7.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -560.63%
Debt to Equity Ratio 0.02
Volume 152,500
Avg Vol 562,024
Day's Range N/A - N/A
Shares Out 95.04M
Stochastic %K 50%
Beta 0.33
Analysts Sell
Price Target $4.00

Company Profile

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer's disease; IGC-1C for the treatment of metabolic disorders and Alzheimer's disease; and IGC-1A to treat metabolic disorders. The comp...

Industry: Biotechnology
Sector: Healthcare
Phone: 301 983 0998
Address:
10224 Falls Road, Potomac, United States
RocketQueen
RocketQueen Feb. 28 at 12:11 AM
$IGC when is full patient enrollment?
0 · Reply
IGC
IGC Feb. 27 at 3:57 PM
$IGC Utility patent applications have been filed to protect key elements of IGC Pharma’s Agentic Harmonization Assistant (AHA), which is being designed as a structured, multi-stage architecture intended to automate dataset alignment and validation across diverse Alzheimer’s datasets. Earlier this year, AHA advanced to the semi-final round of a competitive AI research evaluation program. The Company plans to present additional details regarding AHA’s development roadmap at the upcoming ADPD conference. Read the full press release: https://shorturl.at/aSUbG . . . #ArtificialIntelligence #AlzheimersResearch #DataHarmonization #IGCPharma
0 · Reply
distanceswimmer
distanceswimmer Feb. 26 at 4:25 PM
$IGC buy some, see if they show up, bought 170 shares, never displayed
0 · Reply
QuantumWizard
QuantumWizard Feb. 25 at 11:48 PM
$IGC It seems 2026 is the last operational milestone for all of us to see if this Stock is a Win or Bust
1 · Reply
BearLifeWithShorts
BearLifeWithShorts Feb. 25 at 11:14 PM
$IGC https://www.investorbust.com/post/igc-pharma-stock-stabilizes-near-52-week-lows-as-phase-2-alzheimer-s-trial-catalyst-approaches
0 · Reply
IGC
IGC Feb. 24 at 2:21 PM
$IGC Ascendiant Capital Markets has issued an updated equity research report covering IGC Pharma Statements, opinions, and conclusions in analyst reports reflect the views of the respective analysts and not those of IGC Pharma, which does not endorse or guarantee the accuracy or completeness of such reports. Read the full report: https://ascendiant.com/research-reports/igc-q3-fy26/
0 · Reply
RocketQueen
RocketQueen Feb. 24 at 1:17 AM
$IGC did anyone listen in on the fireside chat?
0 · Reply
prismmarketview
prismmarketview Feb. 23 at 4:08 PM
We’ve added IGC Pharma (NYSE: $IGC) to the PRISM Pharmaceuticals Index. IGC Pharma is advancing IGC-AD1 in its Phase 2 CALMA trial for agitation in Alzheimer’s dementia, with over 70% enrollment complete and trial completion expected in the first half of 2026. With interim data showing a statistically significant reduction in agitation and key milestones ahead, IGC is a clinical-stage name to watch in 2026. https://prismmarketview.com/companies/igc-pharma-inc/
0 · Reply
erevnon
erevnon Feb. 23 at 11:25 AM
Ascendiant Capital maintains IGC Pharma $IGC at Buy and raises the price target from $4.75 to https://marketsblock.com/stock-upgrades-and-downgrades/
1 · Reply
FoxySprout
FoxySprout Feb. 20 at 12:11 PM
$IGC valuation depends almost entirely on the success of one clinical asset. If this drug fails in clinical trials a common outcome in Alzheimer’s research and the company has no diversified pipeline to fall back on, magnifying risk.
0 · Reply
Latest News on IGC
IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research

Feb 26, 2026, 8:30 AM EST - 2 days ago

IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research

IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets

Feb 24, 2026, 8:30 AM EST - 4 days ago

IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets

IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial

Feb 23, 2026, 8:30 AM EST - 5 days ago

IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial

IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances

Feb 17, 2026, 8:30 AM EST - 11 days ago

IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances

IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets

Feb 12, 2026, 8:30 AM EST - 16 days ago

IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets

IGC Pharma Announces Equity Research Update by Alliance Global Partners

Feb 10, 2026, 8:30 AM EST - 18 days ago

IGC Pharma Announces Equity Research Update by Alliance Global Partners

IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center

Feb 9, 2026, 8:30 AM EST - 19 days ago

IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center

IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation

Feb 2, 2026, 8:30 AM EST - 26 days ago

IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York

Jan 22, 2026, 9:00 AM EST - 5 weeks ago

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia

Jan 12, 2026, 9:00 AM EST - 6 weeks ago

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia

IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability

Jan 6, 2026, 8:00 AM EST - 7 weeks ago

IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability

IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial

Jan 5, 2026, 9:00 AM EST - 7 weeks ago

IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial

IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum

Dec 19, 2025, 9:00 AM EST - 2 months ago

IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum

IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines

Dec 15, 2025, 9:00 AM EST - 2 months ago

IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock.

Dec 10, 2025, 9:00 AM EST - 2 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock.

IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

Dec 9, 2025, 9:00 AM EST - 2 months ago

IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease

Dec 2, 2025, 9:00 AM EST - 3 months ago

IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease

IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends

Nov 25, 2025, 9:00 AM EST - 3 months ago

IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital

Nov 17, 2025, 8:30 AM EST - 3 months ago

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital

USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders

Nov 13, 2025, 9:00 AM EST - 3 months ago

USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders

IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025

Nov 10, 2025, 9:00 AM EST - 3 months ago

IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

Nov 3, 2025, 8:52 AM EST - 4 months ago

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"

Oct 22, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences

Oct 14, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences

IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders

Oct 10, 2025, 7:50 PM EDT - 5 months ago

IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease

Oct 7, 2025, 9:00 AM EDT - 5 months ago

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease

IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial

Sep 29, 2025, 9:00 AM EDT - 5 months ago

IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial

IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology

Sep 24, 2025, 9:00 AM EDT - 5 months ago

IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

Sep 22, 2025, 9:00 AM EDT - 5 months ago

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection

Sep 9, 2025, 9:00 AM EDT - 6 months ago

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection

IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada

Sep 2, 2025, 9:00 AM EDT - 6 months ago

IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada

IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome

Aug 28, 2025, 9:00 AM EDT - 6 months ago

IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock.

Aug 27, 2025, 9:00 AM EDT - 6 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock.

IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City

Aug 25, 2025, 9:00 AM EDT - 6 months ago

IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City

IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial

Aug 19, 2025, 9:00 AM EDT - 6 months ago

IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial

IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1

Aug 12, 2025, 9:00 AM EDT - 7 months ago

IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1

IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression

Aug 5, 2025, 9:00 AM EDT - 7 months ago

IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression

IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025

Jul 23, 2025, 9:00 AM EDT - 7 months ago

IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025

IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards

Jul 21, 2025, 9:00 AM EDT - 7 months ago

IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards

IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection

Jul 10, 2025, 3:10 PM EDT - 8 months ago

IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection

IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation

Jun 30, 2025, 9:00 AM EDT - 8 months ago

IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation

IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025

Jun 27, 2025, 8:30 AM EDT - 8 months ago

IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025

IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon

Jun 23, 2025, 8:30 AM EDT - 8 months ago

IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon

IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market

May 22, 2025, 9:30 AM EDT - 10 months ago

IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market

IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting

May 12, 2025, 9:30 AM EDT - 10 months ago

IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting

IGC Pharma Welcomes Strategic Investment from Advisors

Apr 24, 2025, 9:30 AM EDT - 11 months ago

IGC Pharma Welcomes Strategic Investment from Advisors

IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs

Apr 21, 2025, 9:30 AM EDT - 11 months ago

IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs

IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

Apr 8, 2025, 9:30 AM EDT - 11 months ago

IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health

Apr 1, 2025, 9:00 AM EDT - 11 months ago

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health

IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances

Mar 26, 2025, 9:00 AM EDT - 1 year ago

IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances

RocketQueen
RocketQueen Feb. 28 at 12:11 AM
$IGC when is full patient enrollment?
0 · Reply
IGC
IGC Feb. 27 at 3:57 PM
$IGC Utility patent applications have been filed to protect key elements of IGC Pharma’s Agentic Harmonization Assistant (AHA), which is being designed as a structured, multi-stage architecture intended to automate dataset alignment and validation across diverse Alzheimer’s datasets. Earlier this year, AHA advanced to the semi-final round of a competitive AI research evaluation program. The Company plans to present additional details regarding AHA’s development roadmap at the upcoming ADPD conference. Read the full press release: https://shorturl.at/aSUbG . . . #ArtificialIntelligence #AlzheimersResearch #DataHarmonization #IGCPharma
0 · Reply
distanceswimmer
distanceswimmer Feb. 26 at 4:25 PM
$IGC buy some, see if they show up, bought 170 shares, never displayed
0 · Reply
QuantumWizard
QuantumWizard Feb. 25 at 11:48 PM
$IGC It seems 2026 is the last operational milestone for all of us to see if this Stock is a Win or Bust
1 · Reply
BearLifeWithShorts
BearLifeWithShorts Feb. 25 at 11:14 PM
$IGC https://www.investorbust.com/post/igc-pharma-stock-stabilizes-near-52-week-lows-as-phase-2-alzheimer-s-trial-catalyst-approaches
0 · Reply
IGC
IGC Feb. 24 at 2:21 PM
$IGC Ascendiant Capital Markets has issued an updated equity research report covering IGC Pharma Statements, opinions, and conclusions in analyst reports reflect the views of the respective analysts and not those of IGC Pharma, which does not endorse or guarantee the accuracy or completeness of such reports. Read the full report: https://ascendiant.com/research-reports/igc-q3-fy26/
0 · Reply
RocketQueen
RocketQueen Feb. 24 at 1:17 AM
$IGC did anyone listen in on the fireside chat?
0 · Reply
prismmarketview
prismmarketview Feb. 23 at 4:08 PM
We’ve added IGC Pharma (NYSE: $IGC) to the PRISM Pharmaceuticals Index. IGC Pharma is advancing IGC-AD1 in its Phase 2 CALMA trial for agitation in Alzheimer’s dementia, with over 70% enrollment complete and trial completion expected in the first half of 2026. With interim data showing a statistically significant reduction in agitation and key milestones ahead, IGC is a clinical-stage name to watch in 2026. https://prismmarketview.com/companies/igc-pharma-inc/
0 · Reply
erevnon
erevnon Feb. 23 at 11:25 AM
Ascendiant Capital maintains IGC Pharma $IGC at Buy and raises the price target from $4.75 to https://marketsblock.com/stock-upgrades-and-downgrades/
1 · Reply
FoxySprout
FoxySprout Feb. 20 at 12:11 PM
$IGC valuation depends almost entirely on the success of one clinical asset. If this drug fails in clinical trials a common outcome in Alzheimer’s research and the company has no diversified pipeline to fall back on, magnifying risk.
0 · Reply
CarlSpagler
CarlSpagler Feb. 19 at 6:54 PM
$IGC still holding 61k
0 · Reply
dwiz5
dwiz5 Feb. 18 at 9:59 PM
$IGC bought more total 65K worth. G/L
0 · Reply
Golferhack12
Golferhack12 Feb. 18 at 3:28 PM
$IGC when is the last time this company put out a press release I haven't gotten anything in 2 months can anybody post something
0 · Reply
IGC
IGC Feb. 18 at 2:36 PM
$IGC Today at 1:00 p.m. ET, IGC Pharma’s CEO Ram Mukunda and CCO Claudia Grimaldi will participate in a fireside chat hosted by Ascendiant Capital Markets. Topics will include Phase 2 CALMA trial updates and advancements across the Company’s broader pipeline of disease-modifying Alzheimer’s candidates. Register to attend: https://pr.report/ime7 . . . #FiresideChat #HealthcareInnovation #PharmaLeadership #IGCPharma
0 · Reply
CrossSectional
CrossSectional Feb. 17 at 1:11 PM
$IGC Micro-cap cannabis or biotech; speculative.
0 · Reply
angel6
angel6 Feb. 14 at 3:43 PM
$IGC why is this so quiet?
0 · Reply
Golferhack12
Golferhack12 Feb. 13 at 5:33 PM
$IGC I'm curious has anybody else not been receiving any press releases from the company I normally get them on each trade but I haven't seen one in over 2 months please advise
0 · Reply
IGC
IGC Feb. 13 at 3:11 PM
$IGC IGC Pharma’s CEO Ram Mukunda and CCO Claudia Grimaldi will participate in a fireside chat hosted by Ascendiant Capital Markets on Wednesday, February 18, 2026 at 1:00 p.m. ET. The discussion will include enrollment momentum and regulatory developments in the Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer’s disease, as well as progress across the Company’s broader pipeline of disease-modifying Alzheimer’s candidates. Register here: https://pr.report/ime7 #FiresideChat #HealthcareInnovation #PharmaLeadership #IGCPharma
1 · Reply
IGC
IGC Feb. 12 at 12:07 AM
$IGC Alliance Global Partners has published an updated equity research report covering IGC Pharma. All statements, opinions, estimates, projections, and conclusions contained in analyst reports represent the views of the respective analysts and are not those of IGC Pharma. IGC does not endorse, adopt, or guarantee the accuracy or completeness of any analyst report and undertakes no obligation to update or correct the information. Read the full report: https://shorturl.at/kRJzj
0 · Reply
EtherealEquity
EtherealEquity Feb. 9 at 3:21 PM
$IGC India globalization or cannabis; business model is unclear and volatile.
0 · Reply
krishkk
krishkk Feb. 9 at 2:14 PM
$IGC delist next .?
1 · Reply
The_Gambl3r
The_Gambl3r Feb. 8 at 5:03 AM
$IGC 👀👀👀
0 · Reply